A worsening opioid epidemic in the United States and a growing awareness of the effects on the population has injected fresh urgency among America’s politicians to tackle the crisis. It has also placed a renewed focus on Indivior, a London-listed drug developer and manufacturer that specialises in treatment of the addiction.
The biopharma group has been undergoing a lengthy rehabilitation of its own, after legal disputes and patent wars took an understandable toll on investors’ confidence, yet the outlook for the business looks healthier than it has done for some time. Net sales of Sublocade, its next-generation injectable anti-opioid treatment, rose by 88 per cent last year. A growth target for the treatment this year has been set at 56 per cent, or $400
